# Evaluate the Safety of HBM9161 (HL161) Subcutaneous Injection in Patients With Generalized Myasthenia Gravis

> **NCT05332210** · PHASE3 · COMPLETED · sponsor: **Harbour BioMed (Guangzhou) Co. Ltd.** · enrollment: 111 (actual)

## Conditions studied

- Myasthenia Gravis

## Interventions

- **DRUG:** HBM9161 Injection (680mg)

## Key facts

- **NCT ID:** NCT05332210
- **Lead sponsor:** Harbour BioMed (Guangzhou) Co. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-06-30
- **Primary completion:** 2024-04-26
- **Final completion:** 2024-04-26
- **Target enrollment:** 111 (ACTUAL)
- **Last updated:** 2026-04-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05332210

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05332210, "Evaluate the Safety of HBM9161 (HL161) Subcutaneous Injection in Patients With Generalized Myasthenia Gravis". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT05332210. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*